Bio-Techne Corporation (NASDAQ: TECH) today announced the appointment of Amy E. Herr, Ph.D. to serve as an independent director on the Company's Board of Directors beginning on February 1, 2025. Dr.

California members of Congress are blasting incursions by Elon Musk’s team into government’s sensitive data and systems.

It also is exactly the type of story that Darren Cooke, the interim chief innovation and entrepreneurship officer at UC Berkeley ... part of Tuesday's Berkeley Bio Startup Showcase.

Inhibikase’s setback continues biopharma’s losing streak against Parkinson’s, marked by several clinical failures and ...

Shortly after the Hamas massacre, Davidai began speaking out. Since then, he has amassed 105,000 followers on X and 128,000 ...

also partnered with UCB – and felzartamab, an anti-CD38 antibody for IgA nephropathy (IgAN) and other diseases, licensed from Human Immunology Biosciences (HI-Bio) for $1.15 billion upfront ...

According to DelveInsight’s epidemiology model, the total diagnosed prevalent cases of Parkinson’s disease were approximately ...

Today, we're tracking presentations from AbbVie, UCB, WuXi AppTec and several other ... The corporate update came shortly after Samsung Bio revealed its largest production contract in company ...

Corporation (NASDAQ: TECH), a global life sciences company valued at $11.45 billion, has announced the appointment of Dr. Amy E. Herr as an independent director on its Board of Directors. Dr. Herr ...

Antibody drugs have reshaped how we treat diseases. By harnessing the immune system to destroy tumours or temper excessive inflammation in autoimmune disorders, these therapeutics have become ...